In light of preclinical studies that demonstrate higher IR-A/IR-B ratios among individuals with hormone receptor positive, ERBB2 negative breast cancer, a phase I/II clinical trial is presently underway to explore the potential impact of MEDI-573 in conjunction with hormonal therapy within this particular subset of breast cancer patients [97, 98]. Here, ERBB2 is linked to breast cancer.